drugset

drugset / Trial / NCT04730258

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

NCT04730258 ↗

Phase 1/2 Active not recruiting 72 enrolled Treadwell Therapeutics, Inc

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

Timeline

Start: 2021-04-16
Primary completion: 2026-01
Completion: 2026-01

Publications

Murphy T, Mason JM, Leber B, Bray MR, Chan SM, Gupta V, Khalaf D, Maze D, McNamara CJ, Schimmer AD, Schuh AC, Sibai H, Trus M, Valiquette D, Martin K, Nguyen L, Li X, Mak TW, Minden MD, Yee KWL. Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. 2024 Mar;38(3):502-512. doi: 10.1038/s41375-023-02110-9. Epub 2023 Dec 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	—	—
Subject	OCIFISERTIB	Small molecule	32 mg	Oral

Indications